E u r o p e a n S o c i e t y o f C l i n i c a l P h a r m a c y The overall aim of the Society is to develop and promote the rational and appropriate use of medicines by the individual and by society.

ESCP spring workshop: ‘extended responsibilities for pharmacists

in the treatment of acute and chronic conditions’

The ESCP spring workshop will take place in Leiden, The Netherlands on Thursday 15 and Friday 16 June, 2017. The theme of the workshop is: ‘extended responsibilities for pharmacists in the treatment of acute and chronic conditions’. Worldwide, pharma-cists are increasingly involved in cognitive pharmacy services. The responsibilities of pharmacists have shifted from traditional tasks such as compounding and dispensing towards helping patients achieve improved outcomes of pharmacotherapy. This work-shop will give more insight into these de-velopments, providing pharmacists with practical tools to implement new services and to take up extended responsibilities. The workshop consists of four plenary lectures and linked workshops. The lectures will focus on the following topics: 1. How to identify need and plan new pharmacy services 2. Processes and outcomes of pharma-cists as prescribers 3. Developing pharmaceutical care mod-els for patients with specific needs such as transplantations 4. Availability of medicines without pre-scriptions across Europe

Workshops Workshops will be one third longer than those in the ESCP autumn conference, enabling participants to explore the work-shop topics in greater depth. Workshops will be repeated on both conference days enabling participation in two different workshops. Details of the three workshops are as follows: How to create a pharmacy service - In this workshop we will develop a pharmacy service in the field of cardiovascular risk management. The workshops elaborates efficient interventions from pharmacists and how to collaborate with physicians and

nurses. Topics that will be discussed are planning and running the service, monitor-ing and evaluation the outcomes of the intervention including economic outcomes. Participants will do group work on case studies. How to become a prescribing pharmacists - Pharmacists in Scotland have taken up independent prescribing at an astonishingly high rate over the past years. In this work-shop we will elaborate on how pharmacists can evolve to becoming independent prescribers. Topics of the workshop will include developing and evaluating a specific aspect of the service. How to convince the doctor –Several stud-ies suggest that only a proportion of phar-macotherapy recommendations made by pharmacists to physicians are implement-ed. In general, poor pharmacist-physician communication leads to medication errors that can even result in death or permanent loss of function for a patient. Therefore, there is a need to improve pharmacist-physician communication. In this workshop we will analyse several clinical patient cases focusing on effective communication with a physician.

The following speakers will participate in the lectures and workshops: Marcel Bouvy, Professor of Pharmaceutical Care, Utrecht University, the Netherlands Mitja Kos, Associate Professor and Chair of Social Pharmacy, University of Ljubljana, Slovenia Daniel Sabater, Faculty of Pharmacy, Uni-versity of Granada, Spain Derek Stewart, Professor of Pharmacy Practice, Robert Gordon University, Scot-land, United Kingdom Dr Pierrick Bedouch, Head of the Pharmacy Department, Grenoble Alpes University Hospital, Grenoble, France

Kora Doorduyn-van de Stoep (Medicines Evaluation Board, The Netherlands and Dutch representative at Coordination Group for Mutual Recognition and Decen-tralised Procedures - Human (CMDh) at European Medicines Agency) Peter Hartingsveld, Liaison Pharmacist embedded in general practice, Utrecht, The Netherlands Josephine Stutterheim, Teacher / Practi-tioner, Master of Pharmacy, Leiden Univer-sity

Oral Communications Alongside to the lectures and workshops there will be two sessions in which a selec-tion of participants will be invited to pre-sent their abstracts.

Practical information The venue of the meeting is the completely renovated museum of ethnology hosted in a former university hospital from the 18th century. The museum is walking distance from both hotels and from Leiden train station. A direct train service that runs 6 times an hour brings participants of the conference in 15-20 minutes in the depar-tures hall of Schiphol airport. Leiden is one of the oldest cities of The Netherlands and had its heyday in the 17th century due to the world famous cloth industry. The canals of Leiden and the architecture make Leiden a miniature version of Amsterdam. All touristic sights are walking distances of the workshop venue. On Thursday participants will be welcomed

by the Mayor of Leiden during a reception at the City Hall.

Derek Stewart d.stewart@rgu.ac.uk

The tri-monthly newsletter of the European Society

of Clinical Pharmacy

News

ES

CP

New

s —

Ma

y 2

01

7 —

Num

ber

17

5 —

IS

SN

13

53

-03

21

Contents : A Few words 1

ESCP life 2

Articles & Reports 5

ESCP Conferences 7

Announcements 8

News News News

News

News

Contents A few words 1

ESCP life 2

Articles & Reports 5

ESCP conferences 7

Annoucenments 8

1

A F

ew

Wo

rds

ESCP Fellowship 2016

The ESCP Fellowship is awarded in recognition of continued excellence in clinical pharmacy practice and/or research, contribution to the advancement of clinical pharmacy, preferably in Europe, and services for ESCP.

Marcel Bouvy Marcel Bouvy has been an active com-munity pharmacist since 1992 and is research manager at SIR institute for Pharmacy Practice and Policy in Leiden which closely cooperates with Utrecht University where he is Profes-sor of Pharmaceutical care. Marcel has been a frequent visitor of ESCP conferences for almost 20 years during which has he co-authored over 50 scientific abstracts and presented numerous times. He is active in several national and international commit-tees and platforms aiming to improve the safe and effective use of medicines. He is past president of the Scientific Section of Dutch Community Pharmacists (WSO), a founding member of the European Society for Patient Adherence, Compliance and Persistence (ESPACOMP) and member of the editorial board of the International Journal for Pharmacy Practice. His research activities focus on patient adherence, medication safety and include both obser-vational work and evaluation of innovative pharmacy interventions. Marcel is co-

author of > 200 papers in peer reviewed and national journals, both professional and consumer oriented book (chapters) on medicines and research reports. For ESCP he has contributed with numer-ous workshops, and in 2016 he gave a Masterclass on qualitative research meth-ods. Marcel is presently a member of the research committee in ESCP. Anne Gilchrist Anne Gilchrist has always had a special interest in the pre-scribing of medi-cines. She studied Pharmacy at Heriot-Watt University in Edinburgh and then completed a Masters in Clinical Pharmacology at Aberdeen University, having been awarded a Carne-gie Trust Postgraduate Scholarship. She also has a Practice Certificate in Pharmacist Supplementary Prescribing from University of Strathclyde in Glasgow. Anne is a Lead Pharmacist with the NHS Lothian Medicines Management Team, based in Edinburgh, responsible for the

managing the Lothian Joint Formulary. This small and dedicated team coordinates a multiprofessional approach to medicines management and promotes high quality, evidence-based and cost effective prescrib-ing. Previous roles include working in Lon-don for a medical publication, and as a clinical pharmacist. She is an enthusiastic and active member of the European Society of Clinical Pharma-cy, and currently Chair of the Primary and Integrated Care Special Interest Group, having been nominated at the conference in Vilnius in May 2006. She was the editor of the ESCP newsletter from 1999 to 2001. She has presented and coordinated many oral communications, posters and lectures and facilitated workshops at numerous ESCP conferences, and supported and encouraged colleagues to engage with the work of the ESCP.

Financial support for symposium attendees

ESCP would like to assist in the education of clinical pharmacists in developing countries. A way of doing this is to make the ESCP symposia more accessible for pharmacists from these countries. ESCP therefore offers financial support, consisting of free registration to the Europe-an Symposium on Clinical Pharmacy. The pharmacist who requests financial assistance should live and work in a developing country.

Questionnaires for recipients of the ESCP travel grant

Betul Okuyan (Turk-ish), Istanbul, Tur-key. Where do you study/work? Marmara University Faculty of Pharmacy, Dept of Clinical Pharmacy

What is your curriculum in clinical pharmacy? I completed my clinical pharmacy master degree in Marmara University in 2004. I did my PhD studies on clinical pharmacy bet-ween 2004-2010 in Marmara University. I became an Assistant Professor in 2013. Currently I am working at the same position in Department of Clinical Pharmacy at Marmara University. Also, I am an active member of Society of Clinical Pharmacy in Turkey.

Are you a member of ESCP? Yes. Since 2009. What is the title of your poster? I have many posters as one of the co-authors of the studies conducted in our department with our undergraduate and graduate students. I am presenting author of the poster entitled “Evaluation of Ra-tional Antibiotic Dispensing in the Commu-nity Pharmacy Setting: A Simulated Patient Study” What was the main result of your poster? In conclusion, it was observed that dispens-ing antibiotics without prescription was still high, pharmacists did not take comprehen-sive medical or medication history from patients, and pharmacists provided insuffi-cient medication information to the patient regarding suggested medications at com-munity pharmacy settings. To avoid irra-tional antibiotic dispensing, it is essential to educate both health care providers and the general population. Although dispensing

antibiotics without prescription is illegal in some countries, it is necessary to actualise new regulations to avoid antibiotic dispens-ing without prescription. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? No What did you like about the ESCP symposium? I am glad to attend this conference. Thanks for you for this chance. I have a chance to meet researchers and share experiences with them. Additionally the workshops are also nice and well designed. What did you dislike about the ESCP sym-posium? - Would you consider going to another ESCP meeting in the future? Yes, definitely. Do you want to become an ESCP active member in a SIG (special interest group)? Yes, I want to be an active member in a SIG. My preferences is geriatrics.

ES

CP

lif

e

2

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

45th European Symposium on Clinical Pharmacy, jointly organized with NSF

Oslo, Norway, 5-7 October 2016

Clinical pharmacy tackling inequalities and access to health care

Mesut Sancar (Turk-ish), from Istanbul, Turkey. Where do you study/work? Marmara University Faculty of Pharmacy, Dept of Clinical Phar-macy

What is your curriculum in clinical pharmacy? I completed my clinical pharmacy master degree in Marmara University in 1995. I did my PhD studies on clinical pharmacy bet-ween 1996-2002 in Marmara University. I became an Assistant Professor in 2003 and Associate Professor in 2011. Currently I am working at the same position in Depart-ment of Clinical Pharmacy at Marmara University. Also, I am a on of the founder and active executive member of Society of Clinical Pharmacy in Turkey since 1998. I went to US for observation of clinical prac-tice and education in 1998. What is your particular interest in clinical pharmacy? I have had an interest in clinical pharmacy since 1993. I am one of the first master and PhD students working with Prof. Dr. İzzettin who is well known as a founder of clinical pharmacy in Turkey. Therefore, in past 23 years I tried to implement and develop clinical pharmacy and pharmaceutical care education and practice in Turkey with him and other colleagues. I have given many lectures and presentations on this subject in many congresses and continuing education programs organised by Turkish Pharmaceu-tical Associations, Pharmacy Chambers and National Pharmacy Societies. Also I was recently selected as a member of Education Committee of Residency Program in Clinical Pharmacy organised by Turkish Ministry of Health and member of National Accredita-tion Council for Pharmacy Education. How did you hear about ESCP? I heard about ESCP for first time in 1993 during my master education. In 1996, I actively jointed in some collaborative pro-jects undertaken by ESCP in topics such as Acute Myocardial Infarcts Survey in Europe and European Drug Index projects. Was this your first ESCP meeting? No, I have tried to attend to the meetings every year, since 2002. Are you a member of ESCP? Yes, since 2002. What is the title of your poster? I have many posters as one of the co-authors of the studies conducted in our department with our undergraduate and graduate students. I am presenting author for two of these posters; “Determination of

Medication Adherence in Hypertensive Patients in Turkey and North Cyprus” and “Impact of Antiemetic Guideline Consisten-cy on the Patient’s Quality of life” What was the main result of your poster? The aim of my first study is to determine the medication adherence of hypertensive patients by using a 13-item short form of the Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF). According to the answers given to 13 questions by hyperten-sive patients who participated in the study, it is obvious that the level of adherence scores was moderate. In my second poster, 100 chemotherapy naive patients were included in our study and consistency with guidelines was assessed according to MASCC/ESMO 2014. This poster’s result implied guideline inconsistency associated with high incidence of nausea which negatively affects patient’s quality of life. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? No What did you like about the ESCP symposium? It was very exciting for us to be in ESCP symposiums. This year, we attend with 11 colleagues form Turkey. The topic of the symposium is very important especially for the countries, which striving to develop better health care access. During the sym-posium we got a chance to see new devel-opments and shared our results and expe-riences with colleagues. What did you dislike about the ESCP sym-posium? - Would you consider going to another ESCP meeting in the future? Yes, definitely. Do you want to become an ESCP active member in a SIG (special interest group)? Yes, I want to be active member in a SIG. My preference is Paediatrics.

Oznur Ozkan (Turk-ish), from Istanbul, Turkey. What is your curricu-lum in clinical phar-macy? I was graduated from

Anadolu University, Faculty of Pharmacy in 2014. I started my clinical pharmacy educa-tion as a PhD student in 2015 at Marmara University. Our PhD program has two parts; theoretical lessons and a thesis. Currently I am on the theoretical part and my curricu-lum includes topics such as pharmaceutical care, biochemistry, communication skills, clinical practice at the hospital and etc. Also I am working as a research assistant at Marmara University, Faculty of Pharmacy,

Department of Clinical Pharmacy, Istanbul, Turkey. What is your particular interest in clinical pharmacy? I have started to interest in clinical pharma-cy in the last year of my bachelor educa-tion. After my graduation I was accepted to PhD program and this is my second year on my program. At the end of this year I am going to complete the theoretical part and start to work on my thesis. Polypharmacy in geriatrics, especially with elderly diabetic patients this is my particular interest in clinical pharmacy. How did you hear about ESCP? I heard about ESCP from my professors who are active members of ESCP. Especially my Prof. Fikret Vehbi Izzettin supported us to join ESCP meetings. Also I heard from friends who had participated previously in an ESCP symposium. Was this your first ESCP meeting? Yes, it is my first ESCP meeting and my first time in Oslo. Are you a member of ESCP? I am not yet member of ESCP, but I want to become an ESCP active member in the future. What is the title of your poster? I am presenting author of the study entitled ‘The Evaluation of Elderly Patients’ Medica-tion Profile at Community Pharmacy Set-ting’ and I have one more poster as a co-author. What was the main result of your poster? Our study highlights a significant associa-tion between utilisation of potential inap-propriate medication (PIM) uses and both polypharmacy and higher total score of medication regimen complexity index (MRCI) in elderly patients. Pharmacists can evaluate utilisation of PIMs especially elderly patients with used five or more medications and/or a higher score of MRCI. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? No What did you like about the ESCP symposium? In particular for developing countries like ours, the main content of symposium is crucial. So it was very inspirational to see my research area from an international perspec-tive with this topic and meet enthusiastic clinical pharmacists from other countries. Also we are pleased with the kindness and hospitality of organisation team. What did you dislike about the ESCP sym-posium? - Would you consider going to another ESCP meeting in the future? Yes, I really would like to attend the nearest ESCP meeting in the future.

ES

CP

lif

e

3

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

45th European Symposium on Clinical Pharmacy, jointly organized with NSF

Oslo, Norway, 5-7 October 2016

Clinical pharmacy tackling inequalities and access to health care

…/… Financial support for symposium attendees

Esra Küçük (Turkey), from Ankara Where do you study/work? Hacettepe University Faculty of

Pharmacy Department of Clinical Pharmacy What is your curriculum in clinical pharmacy? I’m a master’s student. I’m writing my thesis. What is your particular interest in clinical pharmacy? Oncology How did you hear about ESCP? Internet Was this your first ESCP meeting? Yes Are you a member of ESCP? No What is the title of your poster? Side effects’ assessments of new targeted therapies by a clinical pharmacist in oncol-ogy outpatient clinic What was the main result of your poster? We compared pharmacists’ assessment of cancer immunotherapy side effects in over 200 visits of 43 patients with those of nurs-es’. We found differences in severity as-sessment in 16.5% of them and some side effects were only detected by pharmacists, including oedema, gastrointestinal symp-toms and sensitivity to odour. Our work highlights the potential benefits of a multi-disciplinary approach to assessing (and ultimately) managing side effects of cancer immunotherapy. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? Yes What did you like about the ESCP symposi-um? ESCP members are very kind and polite What did you dislike about the ESCP symposi-um? Congress venue is far away from the city hall. Would you consider going to another ESCP meeting in the future? Yes Do you want to become an ESCP active member in a SIG (special interest group)? Yes, SIG Cancer Care, SIG Medicine Infor-mation.

Gamze Oda-basi (Turkish), from Istanbul Where do you study/work? I work as a lecturer at Uskudar Uni-versity.

What is your curriculum in clinical pharmacy? I am master’s student in Marmara Universi-ty Department of Clinical Pharmacy. At the same time I am PhD special student in Medipol University Department of Clinical Pharmacy. What is your particular interest in clinical pharmacy? I studied in a project which is about diabe-tes. Currently I am working on my master thesis in internal service. In Turkey, there is not a specialty in Clinical Pharmacy now, however in the future, I think there will be some specialties such as diabetes clinical pharmacy or anticoagulant clinical pharmacy. How did you hear about ESCP? I heard about ESCP from my Professor. Was this your first ESCP meeting? Yes, this is my first ESCP meeting. Are you a member of ESCP? No, I’m not. What is the title of your poster? Investigation of Medication Profile of Patients During Hospital Admission What was the main result of your poster? The potential role of pharmacist including medication reconciliation and medication review could improve rationale drug use during hospital admission. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? No, I did not. What did you like about the ESCP symposium? Everyone was very interested to interact with us. Scientific topics were very interest-ing and the workshops were especially beneficial. What did you dislike about the ESCP sym-posium? Congress Hotel was so far away city center and our hotels. Would you consider going to another ESCP meeting in the future? I want to join every year as long as I can. Do you want to become an ESCP active member in a SIG (special interest group)? No, thanks. Now, I haven’t a specialty about Clinical Pharmacy. Maybe in the future, I will have.

Hung-Wei Lin (Taiwanese) from Taipei, Taiwan Where do you study/work? M.S. in Clinical pharmacy, National Taiwan University (Sep 2014- June 2016). Research

Assistant in College of Medicine, National Taiwan University (Aug 2016-now). What is your curriculum in clinical pharmacy? Pharmacotherapy, clinical pharmacokinet-ics, Clinical Pharmacy Practicum (ICU and wards in National Taiwan University Hospi-tal), research methodology, regulatory science, pharmacoeconomics and biostatis-tics… What is your particular interest in clinical pharmacy? Pharmacoepidemiologic studies focus on drug effectiveness and safety, especially in stroke and chronic diseases. Data analysis of claim databases. How did you hear about ESCP? I’ve read serval studies published on IJCP when doing literature review, and noticed that IJCP is affiliated with ESCP. It is well known that ESCP is a leading organisation in clinical pharmacy for Europe, so my professor (Dr. Ho) encouraged me to join the ESCP symposium and submitted ab-stracts Was this your first ESCP meeting? Yes. Are you a member of ESCP? I’m not a member of ESCP yet. What is the title of your poster? “Impacts of a community pharmacy prac-tice experiences on student professional-ism”. What was the main result of your poster? Both ten attributes questionnaire and modified Chisholm’s pharmacy profession-alism instrument were administered to pharmacy students. “Respect for others”, “duty” and “communication” were rated the top three attributes in the survey. Most attributes and professionalism instrument were higher after completing the “Com-munity Pharmacy Practice Experience (CPPE)” course. Did you present your results at an oral poster discussion forum (Pecha Kucha) or as an oral communication? Yes, I presented the results of another research as an oral communication. The topic was “Statin Use is associated with Lower Risk of Epilepsy after Ischemic Stroke: a Population-based Retrospective Cohort Study”. The study used the National Health Insur-ance Research Database of Taiwan to examine the relationship between statin use and the risk of post-stroke epilepsy (PSE). The main finding was that post-stroke statin use was associated with lower risk of PSE.

…/…

ES

CP

lif

e

4

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

45th European Symposium on Clinical Pharmacy, jointly organized with NSF

Oslo, Norway, 5-7 October 2016

Clinical pharmacy tackling inequalities and access to health care

…/… Financial support for symposium attendees

…/… Hung-Wei Lin (Taiwanese) from Taipei, Taiwan What did you like about the ESCP symposium? 1. Practical issues discussed in the plenary sessions and workshops (i.e. new expensive medicines and medication waste….). 2. The schedule of the symposium was not too tight.

3. ESCP symposium was a good chance for me to communicate with pharmacists from other countries (especially in Europe). What did you dislike about the ESCP sym-posium? Everything in the symposium was fine. Would you consider going to another ESCP meeting in the future?

Of course, I would like to attend another ESCP meeting in the future if I have the opportunity. Do you want to become an ESCP active member in a SIG (special interest group)? Yes I would like to become an active ESCP member in the future.

ESCP Research Committee

This year at the ESCP conference in Oslo, members of the Research Committee interviewed several authors of the highest ranked abstracts to get further background to the research and any future intentions.

John Papastergiou and colleagues from

Canada presented several pieces of work at ESCP in Oslo, including the ‘Innovative Canadian Phar-

macogenomic Screening Initiative in Com-munity Pharmacy (ICANPIC) study’.

John talked to the Research Committee about this study which relates to issues of personalised medicines and genomics. John described this as a major opportunity for community pharmacists to embrace phar-macogenomic aspects of medicines selec-tion and appropriateness within their prac-tice.

In this pilot study, two Canadian pharma-cies in Toronto recruited 100 patients taking medicines such as statins, warfarin and antidepressants which could have genomic related issues impacting effectiveness or toxicity. With a simple cheek swab, they are able to predict the extent to which these medicines are likely to work. Initial data are around the types of medicines identified, the frequency and nature of interventions and physician acceptance.

These pilot studies are to be extended to other pharmacies with the ultimate aim of conducting a randomised clinical trial of effectiveness and cost-effectiveness.

Dominik Stämpfli and colleagues from Switzerland discussed their study of ‘Trans-lation and Validation of the CLEO Tool to Assess the Impact of Clinical Pharmacists’ Interventions’.

In describing the rationale for the work Dominik described that the clinical phar-macy services they provide on day-to-day basis should be reviewed and improved regularly to maintain a high quality of care. Notably, this process may be streamlined when there is the possibility to prioritise and to spot patterns. The assessment of potential relevance adds important infor-mation to this process.

CLEO is a tool which helps clinical pharma-cists to assess the potential relevance of their own interventions by creating a unique data set for review purposes. He discussed further the impact of the work in terms of the ability of the CLEO tool to evaluate and to prioritise the wide range of pharmacists' interventions.

Furthermore, it adds qualitative data to the documented interventions and underlying drug-related problems. They also wanted to demonstrate the simplicity and the im-portance of translating the tool from Ger-man and its use in the clinical setting. Fur-ther work will focus on improving the tool in collaboration with the developers and embedding the tool within the Swiss classi-fication system, to be used daily by clinical pharmacists.

Andreja Deticek and colleagues, from Slovenia, presented their work ‘Patient access to medicines for rare diseases in Slovenia and other European countries’.

In describing the need for this study, An-dreja highlighted that management of rare diseases are considered a healthcare priori-ty. With rising numbers of medicines for

rare diseases which are costly and have limited efficacy evidence, the countries are facing challenges in providing patient access to them. Therefore, the purpose of their study was to assess patient access to medicines for rare diseases in 23 European countries in the last decade.

They used the Orphanet list of medicines and the sales data from the IMS MDART database and found large variation across the countries in the three aspects studied. These were: - the number of available medicines varied from 25% to > 90% of the medicines ap-proved in 2005-2014; - median time to their first continuous use ranged between 0.25 and 2.63 years; - and 2.8-31.9 € per inhabitant were spent on these medicines in 2014.

In the future, knowing real-life patient needs would contribute to better under-stand the access to medicines for rare diseases. Hence, patient registries reporting the true disease prevalence and incidence should be initiated and available. She con-sidered that the ESCP conference in Oslo was a great opportunity to present an aspect of access to medicines in such a particular healthcare field like rare diseases in a Europe-wide manner.

In future work, they are going to evaluate the patient access to other innovative medicines and compare it with the access to medicines for rare diseases. Additionally, they will define the importance of specific decision-making criteria concerning medi-cines for rare diseases in Slovenia.

Based on the criteria defined, they will design a decision support tool using a method of multiple-criteria decision analysis.

ES

CP

lif

e

5

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

45th European Symposium on Clinical Pharmacy, jointly organized with NSF

Oslo, Norway, 5-7 October 2016

Clinical pharmacy tackling inequalities and access to health care

…/… Financial support for symposium attendees

New treatment for patients with soft tissue sarcoma Lartruvo recommended for conditional approval Lartruvo is a monoclonal antibody, a type of protein that has been designed to rec-ognise and attach to a protein called plate-let-derived growth factor receptor alpha (PDGFRα). In soft tissue sarcoma this pro-tein is present in high levels or is overactive, causing cells to become cancerous. When Lartruvo attaches to PDGFRα on sarcoma cells, it blocks its activity, thereby slowing down the growth of the cancer.

Soft tissue sarcoma can occur in muscles, blood vessels, fat tissue or in other tissues that support, surround and protect the organs. It is a long-term debilitating and life-threatening disease, particularly when the cancer has spread to other parts of the body. It has a high mortality rate and ac-counts for approximately 2% of all cancer-related deaths.

New treatment for patients with soft tissue sarcoma showed a significant improve-ment in the time patients survived with a combination of doxorubicin plus Lartruvo compared to doxorubicin alone (a median gain of 11.8 months).

The most common side effects of Lartruvo were nausea, musculoskeletal pain, neu-tropenia (low counts of infection-fighting

white blood cells) and mucositis (inflamma-tion and ulceration of the mucous mem-branes lining the digestive tract).

Because soft tissue sarcoma is rare, Lartru-vo received an orphan designation from the Committee for Orphan Medicinal Products (COMP) in 2015.

New medicine for rare, chronic liver disease Ocaliva recommended for conditional approval The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) to Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis (also known as primary biliary cirrhosis). Ocaliva is to be used in combination with another medicine, ur-sodeoxycholic acid (UDCA), in patients who have not responded adequately to UDCA, or on its own in adults who are unable to tolerate treatment with UDCA.

Primary biliary cholangitis is a rare and life-threatening disease that causes the gradual destruction of the small bile ducts in the liver. These ducts transport fluid called bile from the liver towards the intestines where it is used to help digest fats. As a result of the destruction of the ducts, bile builds up in the liver causing damage. As the disease progresses, it leads to liver

cirrhosis (scarring of the liver) and liver failure, and may increase the risk of liver cancer.

Obeticholic acid is a semi-synthetic bile acid that works by activating the farnesoid X receptor (FXR), which controls the produc-tion of bile. By activating this receptor, Ocaliva is expected to reduce the produc-tion of bile in the liver, thus reducing the exposure of the liver to toxic levels of bile acids.

The safety and efficacy of Ocaliva were demonstrated in a phase III study with 216 participants. After 12 months, the propor-tion of patients achieving reductions in levels of their alkaline phosphatase (an indicator of disease progression) was high-er in patients treated with Ocaliva (about 47% compared to 10% in the placebo group). The most common side effects observed with Ocaliva were itching of the skin (pruri-tus) and fatigue.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a conditional marketing authorisa-tion for Ocaliva. Conditional approval is one of EMA’s main mechanisms to facilitate earlier access by patients to medicines that fulfil unmet medical needs.

Gert Laekeman Past President ESCP (2006-2008)

Co-opted member of the Herbal Medicinal Product Committee (EMA)

Have a look at the table of contents for International Journal of Clini-cal Pharmacy. Vol 39 N° 1! It is now available online!

Click on http://link.springer.com/journal/11096/39/1…and enjoy it! Review Articles Assessment of the elderly’s functional

ability to manage their medication: a sys-tematic literature review Risk factors for QTc-prolongation: sys-tematic review of the evidence Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review Short Research Reports Community pharmacist perceptions of delivering post-hospital discharge Medi-cines Use Reviews for elderly patients Evaluation of nucleoside reverse tran-scriptase inhibitor dosing during continuous veno-venous hemofiltration Improvement of time in therapeutic range with warfarin by pharmaceutical intervention

Research Articles The relationship between patients’ knowledge of diabetes therapeutic goals and self-management behaviour, including adherence Impact of pharmaceutical care on cardio-vascular risk among older HIV patients on antiretroviral therapy Assessing pharmacists’ readiness to prescribe oral antibiotics for limited infec-tions using a case-vignette technique Improving the provision of OTC medica-tion information in community pharmacies in Poland Availability and quality of illegitimate somatropin products obtained from the Internet A description of medication errors re-ported by pharmacists in a neonatal inten-sive care unit Impact of a medication therapy man-agement service on the clinical status of

patients with chronic obstructive pulmo-nary disease Effects of economic recession on elderly patients’ perceptions of access to health care and medicines in Portugal Potentially inappropriate prescribing in a population of frail elderly people Improving shared decision-making in adolescents through antibiotic education Evaluation of standardized triple intrathe-cal therapy toxicity in oncohematological paediatric patients Patients’ understanding and use of anal-gesia for postnatal pain following hospital discharge Incidence of bradycardia in paediatric patients receiving dexmedetomidine anes-thesia: a meta-analysis Impact of team-versus ward-aligned clinical pharmacy on unintentional medica-tion discrepancies at admission

EMA news

Art

icle

s &

Re

po

rts

6

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

Organising Committee Clementine Stuijt (NL) Chair Bart van den Bemt (NL) Edwin van Aalten (NL)

Scientific Committee Marcel Bouvy (NL) Chair Fernando Fernandez-Llimos (PT) Lene Juel Kjeldsen (DK) Derek Stewart (UK) Mitja Kos (SI)

Dear colleagues, I hope to meet you in Leiden, The Netherlands on the 15th and 16th of June. The ESCP will organise its spring workshop in the city were the famous Dutch painter Rembrandt was born and worked most of his life. The city is picturesque and very easy to reach from Schiphol airport. But the most important reason to join the workshop is of course its content. The smaller number of the workshop enables us to go in depth in one theme. The theme of this workshop will be extended responsibilities of pharmacists in the treatment of acute and chronic conditions. An estimated one of five people have multiple chronic conditions, this number is continuously rising with the ageing of the population. Manage-ment of chronic conditions is among the most pressing challenges of healthcare systems world-wide. There is a need for more effective manage-ment of the rising numbers of people with multiple chronic conditions. Pharmacists are the third larg-est healthcare professional group in the world after

physicians and nurses. Despite their considerable training, pharmacists are often not perceived as healthcare professionals and thus underutilised. There is increased consensus both among profes-sional pharmacy bodies and policy makers that pharmacists should extend their role in order to more effectively contribute to the safe, effective, and efficient use of drugs. In the Leiden conference we will further elaborate on the strategies to expand the clinical role of pharmacists. We will do so with four plenary lec-tures, but especially in extra-long workshops in which we will discuss innovative concepts such as pharmacists prescribing, how to communicate more effectively with physicians and how to setup a cognitive pharmacy intervention.

I hope to welcome you in Leiden.

Marcel Bouvy President of the Workshop

Presidency Ulrich Jaehde (DE) Hanna Seidling (DE)

Organising Committee Hanna Seidling (DE), Chair Ulrich Jaehde (DE), Chair Erik Gerbrands (NL) Anette Lampert (DE) Markus Lampert (CH) Edwin van Aalten (NL)

Scientific Committee Hanna Seidling, (DE), Chair Ulrich Jaehde (DE), Chair Thilo Bertsche (DE) Siska Desplenter (BE) Tobias Dreischulte (UK) Yolande Hanssen (QA) Torsten Hoppe-Tichy (DE) Hannelore Kreckel (DE) Martin Schulz (DE)

The day before the 46th ESCP Symposium on Clinical Pharmacy (Heidelberg, Germany, October 9th-11th, 2017 - Theme: « Science meets practice - towards evidence-based clinical pharmacy services ») a Mas-terclass of Excellence on « Design and Implementation of Pharmacist-led - Randomized Clinical Trials » will be organised by the ESCP Research Committee in coop-eration with the Department of Clinical Pharma

cology and Pharmacoepidemiology, University of Heidelberg, Germany : Sunday, 8 October 2017, 09:00-16.30 (the day before the Symposium) « Achieving the highest evidence: How to run a RCT? » Hope to welcome you !

14 December 2016 Registration Opening

14 December 2016 Abstract Submission

Opening

15 March 2017 Abstract Submission

Deadline

15 March 2017 Early Bird Registration

Deadline

2 May 2017 Registration Deadline for

Abstract Presenters

The number of participants will be limited to 100.

15 December 2016

Workshop proposals opening

15 March 2017 Workshop proposals

deadline

1st April 2017 Online-registration opening

2 May 2017 Abstract submission open-

ing

1st July 2017 Abstract submission dead-

line

31 July 2017 Early-bird registration

deadline

25 August 2017 Notification to abstract

submitters

13 Sept 2017 Early-bird registration dead-line for abstract presenters

To learn more about the pro-gramme and register, visit:

www.escpweb.org or mail

info@escpweb.org

ES

CP

Co

nfe

ren

ce

s

7

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

For Your Diary

2017

15-16 June Leiden (Netherlands)

ESCP International Workshop Extended responsibilities for pharmacists in the treatment of acute & chronic conditions

9-11 October Heidelberg (Germany)

46th ESCP Symposium on Clinical Pharmacy Science meets practice – towards evidence-based clinical pharmacy service

2018

23-26 October Belfast (Irlande)

47th ESCP Symposium on Clinical Pharmacy

Members' benefits

Membership in ESCP gives you access to the latest and most up to date education in clinical pharmacy. The Society's pan-European community of professionals provides you with a broad network of knowledgeable colleagues.

Members' expertise is founded on profes-sional, clinical experience, on-going re-search and education and specific working environments. We invite you to join ESCP now to benefit from this collective knowledge bank and pan-European expo

sure to clinical pharmacy practice and techniques.

The benefits of ESCP membership include: Latest and most up-to-date scientific research accessible on-line 24 hours a day and delivered to your desk every two months with International Journal of Clini-cal Pharmacy (IJCP) */ Journal. Regular updates and reviews from the clinical pharmacy community via ESCP News. In-depth training and focused infor

mation exchange through participation in Special Interest Groups. Special subscription rates for Adis Jour-nals.

The opportunity to study contemporary clinical pharmacy issues face-to-face with colleagues through ESCP Symposia and Workshops held twice a year (members benefit from substantial registration reduc-tions). Join ESCP today !

Membership 2017

Address: http://www.escpweb.org 2017 Membership fees 1 year Full Membership ......................... € 85 3 years Full Membership........................ € 215 5 years Full Membership........................ € 340 Student Membership.............................. € 25

Dual Membership (SFPC or SIFO) SFPC: see http://sfpc.eu/fr/ SIFO : contact the italian office

ES

CP

New

s M

ay

201

7

Nu

mb

er 1

75

IS

SN

1353-0

321

14 December 2016 Registration Opening

14 December 2016

Abstract Submission

Opening

15 March 2017

Abstract Submission

Deadline

15 March 2017

Early Bird Registration

Deadline

2 May 2017

Registration Deadline for

ESCP European Society of Clinical Pharmacy

ESCP News is published by ESCP Editor: Marie Caroline Husson (France) Page Lay-out: Corinne Tollier (France) Language editing: Ian Millar (UK)

The contents of this publication are compiled in good faith. The publisher accepts no responsibility for omissions or errors.

ESCP International Office SIR Institute for Pharmacy Practice and Policy - Theda Mans-holtstraat 5b - NL-2331 JE Leiden - The Netherlands Tel: +31 645 915 831 - Fax : +31 71 5722431 E-mail: info@escpweb.org / international.office@escpweb.org www.escpweb.org Deadline for the submission of material: for issue number 176 is 15 June 2017.

ES

CP

Ne

ws —

Ma

y 2

01

7 —

Nu

mb

er

17

5 —

IS

SN

13

53

-03

21

An

no

un

ce

me

nts

8